Who is the CEO of Novo Nordisk?

Maziar Mike Doustdar, since 2025, as the AsOf record states with its sources.

Record

Novo Nordisk as of November 10, 2025 · AsOf

organization

Novo Nordisk

Novo Nordisk is a Danish pharmaceutical company, headquartered in Bagsvaerd Denmark. Its CEO is Maziar Mike Doustdar, since 2025. It reported revenue of 290.40B DKK for the period ended December 31, 2024.

CEO: Maziar Mike Doustdar since 2025 sec.gov
Chair: Lars Rebien Sørensen sec.gov
Headquarters: Bagsvaerd Denmark sec.gov
Revenue: 290.40B DKK to 2024-12-31 sec.gov
Employees: 77,349 employee as of 2024-12-31 sec.gov
Ticker

State as of 2025-11-10

1 assertedThe record stands behind this value for the day asked: two independent sources agree, or a primary source states it (alone, at confidence 0.7 or more). Everything else stays on the record, labelled.More in About → fact

Novo Nordisk: state as of 2025-11-10, one row per fact with its value, date, confidence and sources
fact	value	valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About →	confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About →	sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.More in About →

Latest

0 dated events · full timeline →

No dated events on the record yet.

Releases, deals, appointments and policy changes land here once a checked source dates them.

Every claim on the timeline, including undated ones →

Financials

latest period on record · change vs prior year

Revenue

290.40B DKK

2024-12-31+25.0%

every revenue figure →

Net income

100.99B DKK

2024-12-31+20.7%

every net income figure →

Operating income

128.34B DKK

2024-12-31+25.1%

every operating income figure →

Total assets

465.80B DKK

2024-12-31+48.1%

Employees

77,349 employee

2024-12-31+20.3%

every employees figure →

As reported in the linked filings, which may be restated. Not investment advice.

State changes since 2025-05-14

0 changes

No changes since 2025-05-14.

Widen the window with the since date, or compare two dates with the diff.

The full timeline →

About this record

Identifiers8 keys · schema.org snippet

AsOf ID: ent_novo-nordisk
Wikidata: Q818846
X: novonordisk
website: www.novonordisk.com
SEC CIK: 0000353278
fiscal year end: 12-31
SIC industry: Pharmaceutical Preparations (2834)
ticker: NVO

Cite this record in schema.org

"sameAs": ["https://www.wikidata.org/wiki/Q818846", "https://asof.is/record/novo-nordisk"],
"identifier": { "@type": "PropertyValue", "propertyID": "asof", "value": "ent_novo-nordisk" }

Paste into the entity's JSON-LD. Why and how.

Sources on this entity4 sites · 61 citations

sec.govprimary · 53
wikidata.orgsecondary · 5

55 claims on record, 19 currently valid, 36 superseded. Last change 2025-08-07.